drugset / Trial / NCT07348042
Study of RGL-270 Single Drug and Combined With Adebelimab in Patients in Patients at High Risk of Recurrence After Radical Treatment of Malignant Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is a phase I clinical trial of multi-center, open label, dose increase and dose expansion. It aims to evaluate the safety, tolerance, PK characteristics, immunogenicity and initial efficacy of personalized new antigen mRNA vaccine RGL-270 (hereinafter referred to as RGL-270) alone and combined with adebelizumab in patients with high risk of recurrence of malignant solid tumors after radical treatment.
Timeline
- Start
- 2025-09-07
- Primary completion
- 2027-03-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebelimab | Unknown | — | — |
| Subject | RGL-270 | Messenger RNA (mRNA) | — | — |
Indications
No indication recorded.